ABSTRACT Poor diets and obesity are associated with inflammation and insulin resistance (IR), but the physiological regulation of insulin sensitivity (IS) is not completely understood. We report that miR-467, induced by elevated blood glucose levels, decreases inflammation and IR in a diet-induced IR model. In Western diet-fed mice, miR-467 antagonist injections increased IR compared to mice injected with a control oligonucleotide. In mice injected with the antagonist, we detected elevated blood glucose (143 vs 121.7 mg/dL); higher plasma insulin levels (98 vs 63 ng/mL); lower insulin sensitivity; increased adipocyte size; and increased recruitment of macrophages into adipose tissue and pancreas (by 47% in adipose tissue; 44% in pancreas), without increases in weight or lipoproteins and cholesterol levels.
INTRODUCTION
Diet-induced obesity correlates with inflammation and IR (1) . However, the sequence and the causality of the pathological changes leading to the IR are still poorly understood.
Studies in Thbs1 -/mice suggest that a lack of TSP-1 may alleviate chronic inflammation and IR associated with obesity (2) (3) (4) . Macrophage-specific deletion of Thbs1 -/alone was sufficient to protect the animals from IR (2) .
We recently reported that miR-467 is rapidly upregulated by hyperglycemia in endothelial cells (EC) and regulates cancer angiogenesis by targeting TSP-1 mRNA (5; 6) . Others reported that this miRNA prevented vascular inflammation and atherosclerosis development by targeting Lipoprotein Lipase in macrophages (7; 8) .
However, the physiological function of this miRNA and the physiological significance of its rapid upregulation by hyperglycemia remained unknown.
In this work, we employed a diet-induced IR model to examine the effects of miR-467 inhibition on IR. Mice received the weekly systemic injections of a sequence-specific miR-467 antagonist. The effects of the antagonist on glucose and insulin levels, insulin sensitivity, and inflammation in adipose tissue and pancreas were examined in wild type mice (WT) and Thbs1 -/mice to understand the role of miR-467 and its target TSP-1 in regulation of inflammation in tissues and in the development of IR. glucose levels reached the fasting level (90 mg/dL) as measured using AlphaTRAK glucometer, cells were stimulated with 30 mM D-glucose High Glucose, "HG" (Sigma) for 6 hours (RAW 264.7 and BMDM), 3 hours (3T3-L1) or 30 minutes (βTC6).
Transfection of cultured cells
Transfection of the miR-467 antagonist and its control oligo were aided with Oligofectamine (Invitrogen) for 24 hours. Successful transfection with the cholesterolmodified miR-467 mimic was confirmed by fluorescence 24 hours post-transfection using an inverted microscope DMI6000SD (Leica).
Oil Red O Staining
Differentiated 3T3-L1 cells were washed with 1X PBS and fixed in 10% formalin (Electron Microscopy Sciences) for 15' at room temperature (RT), washed with 60% isopropanol (Sigma) , and stained in the Oil Red O solution for 10' at RT.
RNA Extraction and QRT-PCR
RNA was isolated using Trizol reagent (Thermo). Organs were flash frozen in liquid nitrogen and homogenized in Trizol. RNA was quantified using Nanodrop 2000 (Thermo).
To measure miR-467 expression, 1 -2.5 µg of total RNA was first polyadenylated using NCode miRNA First-Strand cDNA Synthesis kit (Invitrogen) or miRNA 1st strand cDNA synthesis kit (Agilent). Real-time PCR amplification was performed using SYBR GreenER™ qPCR SuperMix Universal (Thermo) or miRNA QPCR Master Mix (Agilent).
The miR-467 primer (GTA AGT GCC TAT GTA TATG) was purchased from IDT.
To measure expression of inflammatory markers, 1 -2 µg of total RNA was used to synthesize cDNA using the SuperScript First-Strand cDNA Synthesis System for RT-PCR (Invitrogen). Real-time PCR was performed using TaqMan primers for TNFA, IL6, CCL2, IL1B, IL10, CCL4 (Thermo) and TaqMan Fast Advanced Master Mix (Thermo).
Statistical analysis
Data are expressed as the mean value ± SD (standard deviation). Statistical analysis was performed using GraphPad Prism 5 Software. A p-value of <0.05 was considered statistically significant.
RESULTS

Systemic injections of miR-467 antagonist increase fasting blood glucose and insulin levels in mice
Four-week-old male C57BL/6 WT mice on chow or Western diets were injected with a miR-467 antagonist (2.5 mg/kg) weekly for 32 weeks, starting at 5 weeks of age. At the end of the experiment, fasting blood glucose and insulin levels were measured. As expected, both blood glucose and insulin levels were significantly increased in Western diet-fed mice ( Fig. 1A and B) . Injections of the antagonist resulted in further increase of blood glucose levels in mice on the Western diet ( Fig. 1A) and increased blood insulin levels in chow-fed mice to levels identical to those of mice on the Western diet ( Fig. 1B) .
Systemic injections of miR-467 antagonist decrease insulin sensitivity
Glucose and insulin tolerance tests were performed at the end of the experiment. miR-467 antagonist injections caused higher levels of blood glucose in mice on Western diet 60 -120 min after the glucose injections in GTT (Fig. 1C ). In the ITT, blood glucose levels were also higher at several time points after the injection of insulin in ITT (Fig.   1D ). The Western diet decreased glucose tolerance (GTT area under curve increased from 2042.2 ± 333.7 in chow-fed mice to 2417 ± 402.6 in mice on Western diet, p=0.018, n=10) ( Fig. 1E ) and insulin sensitivity (ITT area under curve increased from 505.8 ± 51.52 in chow-fed mice to 549.8 ± 60.5 in mice on Western diet, p=0.048, n=10) ( Fig. 1F ).
The antagonist injections tended to decrease insulin sensitivity in both the chow and
Western diet groups as compared to the injections of the control oligonucleotide. In mice on chow injected with the antagonist, ITT area under curve was 553.9 ± 119.6, reaching the values similar to the Western diet group, versus 505.8 ± 51.52 in mice injected with the control oligonucleotide (p=0.13, n=10). In Western diet-fed mice, the antagonist increased the area under the curve to 623.5 ± 122.8 versus 549.8 ± 60.5 in mice on Western diet injected with the control oligonucleotide (p=0.05, n=10) ( Fig. 1F ).
Systemic injections of miR-467 antagonist do not affect the weight or lipid profile
The weight of Western diet-fed mice was significantly higher than in the chow-fed mice, as expected ( Fig. 1G ). However, the weight of the animals was not affected by the miR-467 antagonist injections on either diet.
To assess whether lipoprotein levels were affected by the miR-467 antagonist, serum was assayed for levels of high density lipoproteins (HDL), low density lipoproteins (LDL), and cholesterol as described in Methods. Both lipoproteins and cholesterol were significantly higher in mice on the Western diet, as expected ( Fig. 1H ). However, injections of the miR-467 antagonist did not affect the lipid profile on either diet.
Injections of miR-467 antagonist increase macrophage accumulation in adipose tissue
Macrophage accumulation in adipose tissue and pancreas was assessed by immunohistochemistry using an anti-MOMA-2 or anti-CD68 antibody followed by the quantification of the positively stained area ( Fig. 2A and B , respectively).
Western diet-fed mice had significantly increased accumulation of macrophages in adipose tissue ( Fig. 2A, p=0 .0360). Injections of the miR-467 antagonist significantly increased macrophage accumulation in chow-fed mice (47% increase, p=0.0360), from 86.81%±5.514 to levels comparable to mice on the Western diet (128.5%±13.68). There was no further increase in response to antagonist in mice on Western diet (146.3%±26.18, p=0.4698).
In the pancreas, accumulation of macrophages was also increased in mice on Western diet (73% increase, p=0.0172, Fig. 2B ) from 1.00%±0.1106 in chow-fed mice to 1.73%±0.2194 in mice fed the Western diet. Injections of the miR-467 antagonist increased the accumulation of macrophages (44% increase, p=0.0436) in Western dietfed mice from 1.73%±0.2194 to 2.50%±0.3607 with the antagonist. Injections of the miR-467 antagonist also increased the accumulation of macrophages in mice on the chow diet by 62% to 1.624%±0.4787, but it did not reach statistical significance (p=0.1224).
miR-467 antagonist has differential effects on the expression of inflammatory markers in adipose tissue
Expression of Il6, Tnfa, Ccl2, Ccl4, or Il1b was assessed by QRT-PCR in chow or Western diet-fed injected with the control oligonucleotide or the miR-467 antagonist ( Fig. 3C ).
Out of five cytokines, the levels of three, Il6,Tnfa, and Ccl2, were affected by the antagonist: IL6 expression was upregulated by inhibition of miR-467 in mice on chow to levels similar to mice on the Western diet. Tnfa and Ccl2 mRNA levels were decreased in response to the miR-467 antagonist in Western diet-fed mice ( Fig. 3C ). Ccl4 and Il1b expression were not affected by the antagonist.
miR-467 antagonist does not change numbers of circulating monocytes or WBCs
White blood cells (WBC) and monocytes were counted in whole blood samples of mice on both diets injected with the control oligonucleotide or with miR-467 antagonist ( Fig. 2D-E). There was no effect of the antagonist on the numbers of WBC or monocytes in blood in either WT or Thbs1 -/mice. Fibrosis in the adipose tissue affects remodeling and growth of the adipocytes (10-12), thus, adipose tissue sections were stained with Masson's Trichrome to assess extracellular matrix content as a measure of tissue fibrosis ( Fig. 3F ). There was no difference in staining between the mouse groups.
miR-467 in adipose tissue and the effects of the antagonist injections
High glucose upregulates miR-467 in macrophages
Murine macrophages (RAW 264.7) and differentiated human monocyte (THP-1) cell lines were stimulated with high glucose (HG, 30mM D-glucose), and the levels of miR-467 were measured. miR-467 was upregulated by 20.6%±14.31 or 540.3%± 559.5 in response to hyperglycemia (Figs. 4A and C, respectively). Increased miR-467 levels were associated with a decrease in TSP-1 production by the cells (Fig. 4B and D, respectively, *p<0.05). Consistent with the mechanisms of miR-467 upregulation by high glucose described by us earlier (5; 13), both D-glucose and L-glucose had similar effect, indicating the osmolarity change as a stimulus for miR-467 upregulation in macrophages.
In cultured mouse WT bone marrow-derived macrophages (BMDM), miR-467 was significantly upregulated in response to glucose by 38.7%±28.01 ( Fig. 4E, p=0 .05, n=3). miR-467 levels were increased in whole BM by 74.13% in mice that were kept on Western diet for 32 weeks (174.3%±42.72 vs. 100.1%±21.95 in chow, p=0.0004) compared to chow-fed mice ( Fig. 4F ).
miR-467 in pancreas and the effects of the antagonist injections
To assess whether the size and the number of pancreatic islets and the insulin production were affected in pancreas of mice injected with the antagonist, sections of pancreas were stained with the anti-insulin antibody and counterstained with hematoxylin ( Fig. 5A -C). The islet area and insulin secretion in the pancreas were unchanged in miR-467 antagonist-injected mice at the end of the experiment.
We have previously reported that miR-467 promotes angiogenesis (5; 6). The potential effect of miR-467 antagonist on vascularization in the pancreas was assessed by immunohistochemistry with anti-vWF and anti-α-actin antibodies, to visualize the markers of endothelial and vascular smooth muscle cells, respectively (Figs. 5D and E).
There was no change in the vascular cell markers in mice injected with the miR-467 antagonist or in response to the Western diet. At the end of the experiment, the levels of a target of miR-467, TSP-1 were not affected by miR-467 antagonist injections or by the diet (Fig. 5F ).
Mouse pancreatic islets b-cells (bTC-6) were stimulated with high glucose (HG, 30 mM glucose), as described in the Methods, and the levels of miR-467 were measured by QRT-PCR. Glucose-stimulated cells had a 27.7± 4.933% increase in miR-467 expression ( Fig. GH, p= 0 .0284, n=3). In the in vivo experiment with mice on the Western diet, the mean value of pancreatic miR-467 was increased two-fold on the Western diet (208.1%± 173.9vs. 108.6%± 39.04in chow diet), but the difference in the levels at the end of the experiment did not reach statistical significance (Fig. 4H) . miR-467 mimic and antagonist regulate production of inflammatory signals by the cultured macrophages Inhibition of miR-467 by the antagonist prevented upregulation of all four cytokines in response to HG (Fig. 6D ), similar to the WT cells.
TSP-1 knockout eliminates the effects of miR-467 antagonist on blood glucose and insulin levels and IR
To determine whether TSP-1 is a main target of miR-467 in prevention of IR, injections of the miR-467 antagonist were given to Thbs1 -/mice on chow and Western diets.
Unlike in WT mice, inhibiting miR-467 in Thbs1 -/mice did not result in changes of levels of fasting blood glucose or insulin ( Fig. 7A and 7B ), or glucose tolerance and insulin sensitivity ( Fig. 7C and D) . Fasting insulin levels were lower than in WT mice ( Fig. 1B and 7B), but were still increased in Western diet-fed mice (p<0.05).
Similar to WT mice ( Fig. 1) , weight was increased by the Western diet. Notably, in the absence of TSP-1, mice injected with the miR-467 antagonist tended to have lower body weights (Fig. 7E ). Levels of HDL, LDL, cholesterol were upregulated by the Western diet ( Fig. 7F ). All of the indices of lipoprotein metabolism tended to be reduced in mice on the Western diet in response to the miR-467 antagonist.
TSP-1 knockout prevents the accumulation of macrophages in adipose tissue and pancreas of mice injected with the miR-467 antagonist
In Thbs1 -/mice, the effect of the miR-467 antagonist injections on the accumulation of macrophages in adipose tissue and pancreas was prevented ( Figs. 7G and H) .
However, unlike in WT mice where the Western diet increased the accumulation of macrophages in adipose tissue ( Fig. 2A) , in Thbs1 -/mice, there was no difference between the accumulation of macrophages in adipose tissue or pancreas of mice on chow and mice on the Western diet ( Figs. 7G and H) .
Differential effects of the miR-467 antagonist on plasma levels of inflammatory cytokines
Plasma levels of MCP-1, IL-10, VEGF-A, and CXCL1 were measured in WT and Thbs1 -/mice on the chow and the Western diet ( Fig. 8 ). MCP-1, IL-10, and CXCL1 levels were significantly increased by the Western diet in mice of both genotypes (Fig. 8A, B , and C). VEGF-A was not increased by the Western diet (Fig. 8D) .
The miR-467 antagonist increased the level of MCP-1 in WT mice on the Western diet ( Fig. 8A, p=0 .05) but not in Thbs1 -/mice. The antagonist tended to decrease the levels of IL-10 in WT mice on the Western diet (Fig. 8B, p=0 .06), but this effect was lost in the Thbs1 -/mice. There was no effect of the antagonist on CXCL1 or VEGF-A levels ( Fig.   8C and D) .
DISCUSSION
miR-467 levels are normally low or undetectable and are rapidly upregulated in response to high glucose (5; 6; 13) . As was shown in experiments with miRNA mimics and antagonists, miR-467 regulates angiogenesis (5; 6) and vascular inflammation (8; 14) . We hypothesized that physiological functions of this miRNA may be associated with blood glucose handling and may be observed in situations when the regulation of blood glucose levels becomes challenging, e.g., in a model of a diet-induced IR. Inflammation in tissues is associated with IR and often precedes it (10; 15-19) . We found that miR-467 prevents IR and macrophage infiltration of metabolically active tissues in response to the Western diet.
Blocking miR-467 with a sequence-specific antagonist caused increases in fasting blood glucose and insulin and IR. Decrease in insulin sensitivity is frequently associated with the weight gain and changes in lipoprotein profile (20) and is often thought to be a direct consequence of the weight gain and changes in the lipoprotein profile. However, the sequence and causality of events in development of IR are still poorly understood (21) .
When we inhibited miR-467, the development of IR and changes in the blood glucose and insulin levels were uncoupled from the weight gain and impairment of lipoprotein metabolism: in mice injected with miR-467 antagonist, there were no changes in weight or lipoprotein profile on either the chow or the Western diet, demonstrating that IR developed as a direct result of miR-467 inhibition unrelated to the changes in lipid metabolism or weight.
The inhibition of miR-467 increased infiltration of macrophages in the adipose tissue and in the pancreas, suggesting that miR-467 prevents inflammation. The increase in macrophages infiltration in adipose tissue was associated with the increased IL-6 levels.
However, the levels of TNFa, Ccl2, Ccl4, and Il1b were not changed by the antagonist injections in mice on chow diet, and the levels of TNFa and Ccl2 were even reduced in mice on the Western diet injected with the antagonist. These results suggest a specific and complex regulation of inflammatory functions by miR-467. miR-467 antagonist changed the morphology of the adipocytes: the size of the adipocytes tended to be higher in mice injected with the antagonist. Increased adipocyte size is associated with adipocyte hypoxia, increased inflammation in the adipose tissue, and the development of IR (10; 22). miR-467 regulates the production of a potent anti-angiogenic protein TSP-1 (5; 13) . This regulation appears to be central in regulation of angiogenesis in a mouse cancer model miR-467 regulated the pro-inflammatory functions of cultured BMDM: the expression of four cytokines, Tnfa, Il6, Ccl2, and Ccl4, was upregulated by high glucose, but the increase was prevented by the miR-467 antagonist. The effect of miR-467 inhibition on the cytokine production by cultured BMDM was observed in cells from both the WT and Thbs1 -/mice, indicating that TSP-1 is not the mediator of these effects of miR-467.
These results suggest other unidentified miR-467 targets and inflammation-related pathways activated by this miRNA.
TSP-1 is an experimentally confirmed target of miR-467 (5; 6; 13) and the central target of miR-467 in regulation of angiogenesis (5; 13) . Interestingly, in the diet-induced IR model, we found that the increase in the levels of fasting blood glucose and insulin, the development of IR, and the accumulation of macrophages in adipose tissue were TSP-1-dependent, but the production of cytokines by macrophages was not. These results suggest that the inflammation is regulated by miR-467 through multiple targets. The regulation of additional targets of miR-467 was also suggested by the changes of the metabolic indexes in Thbs1 -/mice injected with the antagonist of miR-467: in the absence of TSP-1, the miR-467 antagonist tended to decrease the glucose intolerance, insulin resistance, and also decreased the weights of mice on both diets and the lipoproteins and cholesterol in mice on the Western diet.
In this report, we describe a new physiological role for miR-467: prevention of IR in response to dietary factors inducing inflammation and IR. Our results demonstrated that, by inhibiting the action of miR-467 or of its target TSP-1, one can uncouple IR and lipoprotein metabolism as well as some aspects of inflammation and IR. miR-467 employs multiple targets in regulating the IR, but the prevention of tissue macrophage infiltration and IR depend on TSP-1 as a target of miR-467. Both miR-467 and TSP-1 may prove to be therapeutic targets to prevent and treat IR. In addition to TSP-1, miR-467 appears to have other unidentified targets that may become useful in controlling the weight and lipid metabolism. 
